WP
DSGN icon

Woodline Partners’s Design Therapeutics DSGN Stock Holding History

Woodline Partners’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.1M Sell
700,354
-261,147
-27% -$3.26M 0.03% 534
2026
Q1 		$10.2M Buy
961,501
+17,462
+2% +$177K 0.04% 504
2025
Q4 		$8.86M Buy
944,039
+331,327
+54% +$2.59M 0.03% 488
2025
Q3 		$4.61M Sell
612,712
-164,825
-21% -$826K 0.02% 587
2025
Q2 		$2.62M Buy
777,537
+131,843
+20% +$493K 0.01% 683
2025
Q1 		$2.49M Buy
+645,694
New +$3.08M 0.02% 634

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Woodline Partners's DSGN Position: Q2 2026 in Review

Woodline Partners reduced its Design Therapeutics (DSGN) stake by 27% in Q2 2026, selling an estimated $3.26M and leaving 700,354 shares worth $10.1M. The position accounts for 0.03% of the portfolio, ranked #534.

Woodline Partners first reported a position in DSGN in Q1 2025 and has held it in 6 quarters since. The position peaked at $10.2M in Q1 2026. 136 funds tracked by Wall St. Rank hold DSGN as of Q2 2026.

  • Woodline Partners held 700,354 shares of Design Therapeutics worth $10.1M as of Q2 2026.
  • Woodline Partners sold 261,147 Design Therapeutics shares in Q2 2026, an estimated $3.26M.
  • Design Therapeutics made up 0.03% of Woodline Partners's portfolio in Q2 2026, its #534 holding.
  • Woodline Partners first reported a position in Design Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • Woodline Partners's Design Therapeutics position peaked at $10.2M in Q1 2026.
  • 136 funds tracked by Wall St. Rank held Design Therapeutics as of Q2 2026.

Based on Woodline Partners's 13F filing for Q2 2026, filed 14 Aug 2026.